{"id":"729be151c9d4","type":"article","url":"https://hartvaat.nl/2024/08/13/anti-il-6-therapie-bij-acuut-mi-fase-iia-trial/","title":"Anti-IL-6 therapie bij acuut MI: fase IIa trial","title_en":"Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI).","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.124.069396","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.124.069396","authors":["Antonio Abbate","Benjamin Van Tassell","Vlad Bogin","Roshanak Markley","Dmitry V Pevzner","Paul C Cremer","Imad Meray","Dmitry V Privalov","Angela Taylor","Sergey A Grishin","Alina N Egorova","Ekaterina G Ponomar","Yan Lavrovsky","Mikhail Yu Samsonov"],"significance":7,"published":"2024-08-13","source_date":"2024-08-13","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/farmacologie/colchicine-cardiovasculair/"],"congress":"","summary_en":"This phase IIa trial of interleukin-6 blockade in acute MI demonstrated significant reduction in hsCRP, testing a more targeted anti-inflammatory approach than IL-1β inhibition for attenuating the acute inflammatory response after myocardial infarction.","created":"2026-07-03T10:31:06Z","updated":"2026-07-03T13:30:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Fase IIa trial onderzocht interleukine-6 blokkade bij acuut MI om de inflammatoire respons te dempen. Het middel verminderde hsCRP significant, wat het anti-inflammatoire concept bij MI verder ontwikkelt na CANTOS en COLCOT.","abstract_original":""}